Pharmaceutical Testing

The BD Veritor™ System Flu A+B Control Swab Set is intended for use with the BD Veritor™ System Reader and Flu A+B Test. Contains 10 tests per kit. This control material is CLIA Waived. Requires refrigeration for storage, CLIA Waived.

The BD Veritor™ System is a chromatographic immunoassay with an instrumented read for the direct and qualitative detection of RSV fusion protein from a direct nasopharyngeal swab from patients suspected of having a viral respiratory infection, This test is intended for in vitro diagnostic use to aid in the diagnosis of RSV infections in infants and pediatric patients under the age of 20 years, It is to be used in conjunction with the BD Veritor System Reader.

The BD Veritor™ System is a chromatographic immunoassay with an instrumented read for the direct and qualitative detection of RSV fusion protein from a direct nasopharyngeal swab from patients suspected of having a viral respiratory infection, This test is intended for in vitro diagnostic use to aid in the diagnosis of RSV infections in infants and pediatric patients under the age of 6 years, It is to be used in conjunction with the BD Veritor System Reader.

The BD Veritor™ System for Rapid Detection of Group A Strep is a rapid chromatographic immunoassay for the direct and qualitative detection of Group A Streptococcus antigen from throat swab of symptomatic patients, It is intended to be used in conjunction with the BD Veritor System Reader as an aid in the diagnosis of Group A Strep.

The BD Veritor™ System for Rapid Detection of Flu A+B is a rapid chromatographic immunoassay for the direct and qualitative detection of influenza A and B viral nucleoprotein antigens from nasopharyngeal wash, aspirate and swab in transport media samples from symptomatic patients, The BD Veritor System for Rapid Detection of Flu A+B is a differentiated test, such that influenza A viral antigens can be distinguished from influenza B viral antigens from a single processed sample using a single device.

Kits may be stored at 2 - 30°C: Do not freeze, Reagents and devices must be at room temperature (15 - 25°C) when used for testing, Acceptable specimens for testing with the BD Veritor System Flu A+B test include nasal swabs and nasopharyngeal (NP) swabs, CLIA Waived.

Rapid detection of SARS-CoV-2, Fast results in 15 minutes, Results are analyzed and digitally displayed by the BD Veritor Analyzer, Advanced particle technology for enhanced sensitivity, Authorized by the FDA under an EUA, pending FDA clearance / approval, 30 tests per kit, CLIA waived.

Analyzes the Influenza A & B, RSV & Group A Strep Test in 5 to 10 Minutes, Advanced Particle Technology for Greater Accuracy, Adaptive Read Technology Reduces False-Positive Results, Operation Simplicity for Streamlined Workflow, Compatible with External Printer & Veritor™ InfoScan Module.

The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, Not for any other viruses or pathogens, The BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens, These products are only authorized for the duration of the declaration that circumstances exist justifying the authorization of  emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food,  Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner, These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories.